METX Stock Overview
A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
ME Therapeutics Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$3.80 |
52 Week High | CA$7.50 |
52 Week Low | CA$0.26 |
Beta | 0 |
11 Month Change | -30.91% |
3 Month Change | 153.33% |
1 Year Change | 3,700.00% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 520.41% |
Recent News & Updates
Recent updates
Shareholder Returns
METX | CA Biotechs | CA Market | |
---|---|---|---|
7D | 8.6% | 8.5% | 0.5% |
1Y | 3,700.0% | 13.2% | 22.2% |
Return vs Industry: METX exceeded the Canadian Biotechs industry which returned 13.2% over the past year.
Return vs Market: METX exceeded the Canadian Market which returned 22.2% over the past year.
Price Volatility
METX volatility | |
---|---|
METX Average Weekly Movement | 75.2% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.4% |
10% most volatile stocks in CA Market | 17.8% |
10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: METX's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: METX's weekly volatility has increased from 49% to 75% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Salim Dhanji | www.metherapeutics.com |
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.
ME Therapeutics Holdings Inc. Fundamentals Summary
METX fundamental statistics | |
---|---|
Market cap | CA$89.81m |
Earnings (TTM) | CA$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs METX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
METX income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$0 |
Earnings | CA$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did METX perform over the long term?
See historical performance and comparison